New CEO for Australian Research Council

Tuesday, 29 May, 2012

Professor Aidan Byrne is set to contribute greatly to Australia’s strong research future as the new Chief Executive Officer of the Australian Research Council (ARC).

The ARC provides advice to the Australian government on research matters, manages $849 million of the government’s investment in high-quality research and manages the internationally recognised Excellence in Research for Australia (ERA) research evaluation exercise.

Announcing the appointment yesterday, the Minister for Tertiary Education, Skills, Science and Research, Senator Chris Evans, said it was an important step for the nation’s research effort.

“Professor Byrne’s appointment will ensure that Australia continues to be a leading example of an innovative and robust science and research system,” Senator Evans said.

“Professor Byrne is a distinguished leader in research and research management at the Australian National University and has been for 20 years. He brings to the ARC a wealth of industry knowledge and expertise particularly in nuclear physics, physical and mathematical sciences as well as engineering.”

Professor Byrne is currently the Dean of Science at the ANU and the Director of the ANU College of Physical and Mathematical Science. He will commence his role as CEO on 23 July. ARC Executive General Manager Leanne Harvey will continue to act as CEO until this time.

Former CEO Professor Margaret Sheil left the ARC last month after almost five years.

“I thank Professor Sheil for her tremendous stewardship of the ARC since 2007 and wish her all the best in her new position as Provost of the University of Melbourne,” Senator Evans said.

Related News

Virologist receives GSK Award for AI-based disease detection

Professor Edward Holmes has received the 2025 GSK Award for Research Excellence for his...

WA Govt creates Science and Technology Council

The council will offer independent advice on emerging opportunities and challenges, promoting...

Billion-dollar deal for UQ's molecular clamp vaccine tech

Sanofi has entered into an agreement to acquire Vicebio, a biotech company formed in 2018 to...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd